Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
127 results about "Cannabinoidergic" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cannabinoidergic, or cannabinergic, means "working on the endocannabinoid neurotransmitters". As with terms such as dopaminergic and serotonergic, related proteins and cellular components involved endocannabinoid signaling, such as the cannabinoid (CB₁) receptor, as well as exogenous compounds, such as phytocannabinoids or other cannabinoids which modulate the activity of endocannabinoid system, can be described as cannabinoidergic.
Heteroindanes: a new class of potent cannabimimetic ligands
One aspect of the invention is concerned with cannabimimetic heteroindane analogs having affinities and / or selectivities for a cannabinoid receptor. A further aspect of the invention is concerned with pharmaceutical preparations employing the inventive analogs and methods of administering therapeutically effective amounts of the inventive analogs to provide a physiological effect.
Owner:UNIV OF CONNECTICUT
Cannabinoid-containing plant extracts as neuroprotective agents
The invention relates to the use of cannabinoid-containing plant extracts in the prevention or treatment of neural degeneration. In particular, the invention relates to use of one or more cannabinoid-containing plant extracts in the prevention or treatment of neural degeneration, wherein the one or more cannabinoid-containing plant extracts comprise: i) a cannabinoid-containing fraction; and ii) a non-cannabinoid containing fraction.
Owner:GW RES LTD
Use of cannabinoids in the treatment of epilepsy
The present disclosure relates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; CDKL5; Dup15q; Jeavons syndrome; Myoclonic Absence Epilepsy; Neuronal ceroid lipofuscinoses (NCL) and brain abnormalities. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
Owner:GW RES LTD
Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD.
Owner:GW PHARMA LTD
Use of cannabinoids in the treatment of epilepsy
The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
Owner:GW RES LTD
Use of cannabinoids in the treatment of epilepsy
ActiveUS20170007551A1Reduce in quantityReduce doseNervous disorderHydroxy compound active ingredientsAicardi's syndromeFocal Epilepsies
The present invention relates to the use of cannabidiol (CBD) in the treatment of focal seizures. In one embodiment the patients suffering from focal seizures are children and young adults. CBD appears particularly effective in reducing focal seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; CDKL5; Neuronal ceroid lipofuscinoses (NCL); febrile infection related epilepsy syndrome (FIRES); Aicardi syndrome and brain abnormalities in comparison to other seizure types. Significantly CBD additionally is very effective in the reduction of a sub-type of focal seizures, focal seizures with impairment.
Owner:GW RES LTD
Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD.
Owner:GW PHARMA LTD
Cannabinoid derivatives, methods of making, and use thereof
InactiveUS20070167514A1Wide diversityHigh affinityBiocideSenses disorderCannabinoidergicPerylene derivatives
1′-substituted cannabinoid derivatives of delta-8-tetrahydrocannabinol, delta-9-tetrahydrocannabinol, and delta-6a-10a-tetrahydrocannabinol that have affinity for the cannabinoid receptor type-1 (CB-1) and / or cannabinoid receptor type-2 (CB-2). Compounds having activity as either agonists or antagonists of the CB-1 and / or CB-2 receptors can be used for treating CB-1 or CB-2 mediated conditions.
Owner:UNIV OF TENNESSEE RES FOUND
Transdermal cannabinoid patch
InactiveUS20160022627A2Hydroxy compound active ingredientsOrganic non-active ingredientsCannabisTransdermal patch
The present invention includes a transdermal patch which contains a pharmaceutically effective amount of a cannabinoid for delivery of the cannabinoid to the bloodstream of a user. The patch may comprise the following components: a backing; and a skin-adhesive polymer matrix attached to one side of the backing, which includes a cannabinoid, a carrier agent, a terpene, and a permeation agent. The cannabinoid is capable of diffusing from the matrix in the transdermal patch into the bloodstream of the user, and may be used in methods for treating a patient suffering from a condition such as pain, nausea and emesis, convulsions, muscle spasm, inflammation, depression, and cachexia.
Owner:MM TECH HLDG LLC
Use of cannabinoids in the treatment of epilepsy
ActiveUS20200297656A1Reduce in quantityReduce doseNervous disorderHydroxy compound active ingredientsAicardi's syndromeYoung adult
The present invention relates to the use of cannabidiol (CBD) in the treatment of focal seizures. In one embodiment the patients suffering from focal seizures are children and young adults. CBD appears particularly effective in reducing focal seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; CDKLS; Neuronal ceroid lipofuscinoses (NCL); febrile infection related epilepsy syndrome (FIRES); Aicardi syndrome and brain abnormalities in comparison to other seizure types. Significantly CBD additionally is very effective in the reduction of a sub-type of focal seizures, focal seizures with impairment.
Owner:JAZZ PHARM RES UK LTD
Use of cannabinoids in the treatment of epilepsy
ActiveUS10709671B2Nervous disorderHydroxy compound active ingredientsAicardi's syndromeFocal Epilepsies
Owner:GW RES LTD
Synthetic endogenous cannabinoids analogues and uses thereof
InactiveUS6531636B1Avoid actionPromote absorptionBiocideEther/acetal active ingredientsMigraineBULK ACTIVE INGREDIENT
The present invention relates to a compound of the general formula (I) which is a non-hydrolysable analogue of endogenous cannabinoids, which are found to be more potent therapeutic agents as they are more stable, for example, to hydrolytic cleavage in the gastrointestinal tract. The cannabinoid analogues of the invention have a therapeutic value. Therefore, pharmaceutical compositions comprising as active ingredient a therapeutically effective amount of at least one compound of the invention may be prepared. Such compositions may be used as anti-inflammatory, anti-asthmatic, analgetic, hypotensive, antiemetic or anti-spasmodic compositions, and as compositions for treating and / or preventing glaucoma or migraine, or as compositions for relieving symptoms of multiple sclerosis and mood stimulating compositions.
Owner:YISSUM RES DEV CO OF THE HEBREWUNIVERSITY OF JERUSALEM LTD
3-substituted coumarin derivative and use thereof
InactiveCN103265517AHigh calcium flux activityGood choiceNervous disorderOrganic chemistryCannabinoid Receptor CB2Pharmaceutical drug
The invention provides a 3-substituted coumarin derivative, and pharmaceutically acceptable salts, solvates, hydrates or crystal forms thereof. The above compound has a high calcium flow activity and a very good selectivity on a human derived cannabinoid receptor CB2, and is a specific agonist or inverse agonist of the cannabinoid receptor CB2. The compound is an active ligand of a novel cannabinoid II receptor CB2, and compounds of the above kind and pharmaceutically acceptable salts, solvates, hydrates or crystal forms thereof have high calcium flow activities and a very good selectivity on the human derived cannabinoid receptor CB2. The compound is the specific agonist or inverse agonist of the cannabinoid receptor CB2, and can be applied to the preparation of medicines for treating, preventing and inhibiting CB2 receptor mediated diseases. The structure of the derivative is represented by a general formula A shown in the specification.
Owner:ZHEJIANG UNIV +1
Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
InactiveUS20060160776A1Increase frequencyImprove severityBiocidePeptide/protein ingredientsInjury causeMedicine
The present invention provides compositions and methods for the treatment of central nervous system damage in a subject. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic condition or a central nervous system traumatic injury comprising the administration to a subject of a cannabinoid agent in combination with a cyclooxygenase-2 selective inhibitor.
Owner:PHARMACIA CORP
Bicyclic CB2 cannabinoid receptor ligands
The present invention relates to non-classical cannabinoids that are ligands of the peripheral cannabinoid receptor CB2, and to pharmaceutical compositions thereof comprising as an active ingredient novel (+) alpha-pinene derivatives, which are useful for prevention and treatment of autoimmune diseases including but not limited to rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, diabetes mellitus type I, hepatitis, psoriasis, tissue rejection in organ transplants, malabsorption syndromes such as celiac disease, pulmonary diseases such as asthma and Sjögren's syndrome, inflammation including inflammatory bowel disease, pain including peripheral, visceral, neurophathic inflammatory and referred pain, muscle spasticity, cardiovascular disorders including arrhythmia, hypertension and myocardial ischemia, neurological disorders including stroke, migraine and cluster headaches, neurodegenerative diseases including Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's chorea, prion-associated neurodegeneration, CNS poisoning and certain types of cancer.
Owner:PHARMOS
Composition and methods to improve stability, dosing, pharmacodynamics and product shelf life of endocannabinoids, phytocannabinoids and synthetic cannabinoids delivered by nasal inhaer
InactiveUS20180000727A1Potent analgesicEnhance pharmacological effectsOrganic active ingredientsPowder deliveryEndogenous cannabinoidPharmacodynamic Study
An inhaler-delivery-device-packaged homogenate of solid heterogeneous-lipid particulates carrying lipophilic cannabinoid receptor agonists and / or antagonists, wherein the solid heterogeneous-lipid particles comprises: one (or more) lipid(s) whose melting point(s) is (are) substantially above room temperature; in combination with, one (or more) lipid(s) whose melting point(s) is (are) substantially less than room temperature.
Owner:WILLINSKY MICHAEL
Cannabinergic lipid ligands
ActiveUS8202893B2High affinityHigh selectivityBiocideSenses disorderReceptor subtypeEndogenous cannabinoid
One aspect of this disclosure relates generally to lipid compounds that exert diverse effects in the endocannabinoid system, such as regulating CB1 and CB2 receptor or moderating other bio-macromolecules within the endocannabinoid system. Some of the compounds showed improved receptor binding affinity, and / or improved receptor subtype selectivity, and improved bio-stability. Some of the compounds exhibit activities to regulate the enzymes that moderate the bio-disposal of endogenous cannabinoids, such as the fatty acid amide hydrolase (FAAH). Some of the compounds exhibit activities to inhibit the anandamide transporter. Other aspects of the invention are pharmaceutical preparations employing these ligands and methods of administering therapeutically effective amounts of the preparations to provide a physiological effect.
Owner:UNIV OF CONNECTICUT
Composition and Method For Treating Seizure Disorders
ActiveUS20180161285A1Inhibit hepatic metabolic effectIncrease the amount addedNervous disorderHydroxy compound active ingredientsCannabinoidergicCannabidiol
The invention provides compositions and methods for treating seizure disorders such as epilepsy in humans and animals using, in a first embodiment, the combination of (i) an effective amount of a barbiturate drug, such as phenobarbital or primidone, which solely enhances GABAergic inhibition in a patient suffering a seizure disorder; and (ii) phytocannabinoid cannabidiol (CBD) in a dosage amount sufficient to overcome the hepatic metabolic effect stimulated by the barbiturate drug and provide bioavailable CBD to the patient in clinically efficacious amounts.
Owner:INDIA GLOBALIZATION CAPITAL
Apparatus, methods and composition for synthesis of cannabinoid compounds
ActiveUS20180346866A1Bioreactor/fermenter combinationsBiological substance pretreatmentsChemical compoundCannabinoidergic
The disclosure provides systems and methods for producing a cannabinoid product, which comprises contacting a cannabinoid precursor in a first phase with a cannabinoid synthase in a second phase, wherein the first phase and the second phase are substantially immiscible or immiscible. The disclosure also provides a composition comprising the cannabinoid precursor in a first phase and a cannabinoid synthase in a second phase, wherein the first phase and the second phase are substantially immiscible or immiscible.
Owner:TEEWINOT LIFE SCI CORP
Quinazoline dione derivatives and preparation method and application thereof
The invention provides novel quinazoline dione derivatives and a preparation method and application thereof. The compounds include compounds with the structure shown in the general formula V in the description and pharmaceutically acceptable salts or hydrates thereof. The compounds are active ligands of novel cannabinoid II receptors (CB2) and can be used for preparing medicine for treating, preventing and relieving CB2 receptor-mediated diseases, wherein the medicine is an agonist or partial agonist or inverse agonist or antagonist of CB2 receptors.
Owner:ZHEJIANG UNIV +1
Cannabinoid Profiling Using Nanopore Transduction
ActiveUS20190376929A1Material analysis by electric/magnetic meansBiological testingElectrophoresesMembrane channel
Embodiments profile cannabinoids using a nanopore detector. Embodiments use an applied potential to electrophoretically draw a nanopore blockade reporter molecule into a nanopore channel to establish an electrophoretic molecular channel-capture for the reporter molecule. The reporter molecule includes one of an aptamer or a monoclonal antibody and has a specific binding to at least one of: a specific cannabinoid, a particular cannabinoid isoform; or a specific cannabinoid family. Embodiments receive a blockade channel current signal in response to a nanoscale membrane channel of the nanopore detector being partially blockaded by a presence of the reporter molecule non-covalently bonded to the membrane channel. Embodiments receive a blockade signal for the reporter molecule that is toggling between more than one level.
Owner:CANNAPTIC BIOSCI LLC
Method and system for providing a personalized cannabinoid treatment regimen
Methods and systems for providing a personalized cannabinoid treatment regimen to a patient include obtaining genotypes of single nucleotide polymorphisms (SNPs) from a patient's genetic test and modifying base values, such as base dosages or base ratios, using weighting values reflecting the obtained genotypes to obtain regimen values for treating the patient. The regimen values take into account expected responses to cannabinoids based on patient genetic information.
Owner:GREENWAY DNA INC
Method and apparatus for real-time detection of human cannabinoid intoxication
A method for quantifying the intoxicating affect of natural and synthetic Cannabinoids on Humans. The method includes the capacity to measure a human's psychoactive intoxication as a function of Cannabinoid-Mediated Depolarization-Induced Suppression of Inhibition (C-DISI) relative to the Cannabinoid Receptors found in the Human brain. A Method incorporating the ability to also quantify the affects of Cannabinoids on the various Cannabinoid Receptors found in the Human body. Neurons are used as transistors in a solid state electronic configuration with an apparatus to measure the toxicity of a given aqueous solution comprised of one or more Cannabinoid analytes. Said method incorporates a novel recycling process affiliated with analyte acquisition & testing.
Owner:PEREZ JOHN SCOTT
Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation
InactiveUS20080200501A1Suitable for treatmentReducing tobacco cravingBiocideSenses disorderDiseaseCannabinoid
The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and / or disorders modulated by a cannabinoid receptor (such as pain, neurodegenative disorders, eating disorders, weight loss or control, and obesity).
Owner:GLENMARK PHARMA SA
Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids
ActiveUS20170319607A1Shorten the progressHydroxy compound active ingredientsLiposomal deliveryDiseaseCannabinoid
This invention relates to compositions containing combinations of a balanced phosphatidylcholine composition and one or more cannabinoids, a natural or synthetic derivative thereof, or a salt thereof, and kits containing such combinations and methods of using such combinations to treat subjects suffering from an imbalance of fatty acids and related diseases or disorders. This invention also relates to the synergistic effect of such combination therapies in humans.
Owner:BODYBIO INC
Cannabimimetic lipid amides as useful medications
InactiveUS7161016B1High affinityHigh selectivityFatty acid chemical modificationOrganic compound preparationCancer and nauseaMetabolic stability
Novel analogs of arachidonylethanolamide are presented which have higher affinities for the cannabinoid CB1 and / or CB2 receptor sites. Further, most of the analogs exhibit greater metabolic stability than arachidonylethanolamide. The improved receptor affinity and selectivity and / or greater metabolic stability make these analogs therapeutically useful as medications for relief of pain caused by cancer and nausea caused by chemotherapy, as well as for peripheral pain. The compounds may also be useful as oral and topical contraceptives, in suppression of the immune system, enhancement of appetite and in treatment of psychomotor disorders, multiple sclerosis and hypertension.
Owner:UNIV OF CONNECTICUT
Food and beverage compositions infused with lipophilic active agents and methods of use thereof
PendingCN107072278AImprove bioavailabilityAntibacterial agentsOrganic active ingredientsCannabinoidActive agent
Aspects described herein relate to food and beverage compositions infused with lipophilic active agents and methods of use for the treatment of a variety of disorders. More particularly, aspects described herein relate to food and beverage compositions infused with lipophilic active agents such as cannabinoids, nicotine, nonsteroidal anti-inflammatories (NSAIDs), and vitamins, that provide enhanced bioavailability of the lipophilic active agents in a subject, and that mask unpleasant tastes of lipophilic active agents.
Owner:波维瓦公司
Novel Cannabinergic Compounds and Uses Thereof
Disclosed are compounds and compositions that modulate cannabinoid receptors, methods of modulating cannabinoid receptors, and methods of treating various disorders related to the modulation of cannabinoid receptors. This disclosure is directed to methods of treating cannabinoid dependence, neuropathy, inflammation, glaucoma, a neurodegenerative disorder, a motor function disorder, a gastrointestinal disorder, hypothermia, emesis, loss of appetite, or anorexia associated with AIDS.
Owner:NORTHEASTERN UNIV
Cannabinoid Production by Synthetic In Vivo Means
In some aspects of the design, novel forms of geranylpyrophosphate:olivetolate geranyltransferase; of olivetol synthase or of geranyl pyrophosphate synthase; of geranylgeranyl pyrophosphate synthase; of olivetolic acid cyclase; and / or of olivetolic acid synthase for making large scale amounts of cannabinoids in cells, in vitro are presented.
Owner:BIOTIC SCI INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com